A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

por Wolz, Olaf-Oliver, Kays, Sarah-Katharina, Junker, Helga, Koch, Sven D., Mann, Philipp, Quintini, Gianluca, von Eisenhart-Rothe, Philipp, Oostvogels, Lidia
Publicado 2022

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective

por Kleinlützum, Dina, Hanauer, Julia D. S., Muik, Alexander, Hanschmann, Kay-Martin, Kays, Sarah-Katharina, Ayala-Breton, Camilo, Peng, Kah-Whye, Mühlebach, Michael D., Abel, Tobias, Buchholz, Christian J.
Publicado 2017

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

por Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Publicado 2023

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

por Sáez-Llorens, Xavier, Lanata, Claudio, Aranguren, Elaine, Celis, Carlos R., Cornejo, Rubelio, DeAntonio, Rodrigo, Ecker, Lucie, Garrido, Diegi, Gil, Ana I., Gonzales, Marina, Hess-Holtz, Morgan, Leroux-Roels, Geert, Junker, Helga, Kays, Sarah-Katharina, Koch, Sven D., Lazzaro, Sandra, Mann, Philipp, Quintini, Gianluca, Srivastava, Barkha, Vahrenhorst, Dominik, von Eisenhart-Rothe, Philipp, Wolz, Olaf-Oliver, Oostvogels, Lidia
Publicado 2022